• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.格罗菲他单抗可刺激中枢神经系统肿瘤的免疫细胞浸润，并在继发性中枢神经系统淋巴瘤中诱导临床应答。
Blood. 2024 Jul 25;144(4):457-461. doi: 10.1182/blood.2024024168.
2
Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.皮下注射依泊妥单抗治疗复发或难治性B细胞非霍奇金淋巴瘤后的群体药代动力学
Clin Pharmacokinet. 2025 Jan;64(1):127-141. doi: 10.1007/s40262-024-01464-2. Epub 2024 Dec 21.
3
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.肿瘤内免疫细胞亚群的分子评估及奥妥珠单抗（一种 CD20×CD3 双特异性抗体）治疗复发/难治性 B 细胞非霍奇金淋巴瘤患者耐药的潜在机制。
J Immunother Cancer. 2024 Mar 21;12(3):e008338. doi: 10.1136/jitc-2023-008338.
4
CD20×CD3 Bispecific Antibodies in B-NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research.B细胞非霍奇金淋巴瘤中CD20×CD3双特异性抗体：临床研究中的转化科学、药代动力学、药效学及剂量策略综述
Clin Transl Sci. 2025 Jun;18(6):e70250. doi: 10.1111/cts.70250.
5
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting.双特异性抗体靶向 CD20xCD3 在成人 B 细胞淋巴瘤免疫治疗中的作用：第 65 届美国血液学会 2023 年年会的见解。
Expert Opin Biol Ther. 2024 May;24(5):321-326. doi: 10.1080/14712598.2024.2351995. Epub 2024 May 8.
6
Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.用抗CD20×抗CD3双特异性双抗体有效抑制人B细胞淋巴瘤异种移植瘤
Cancer Lett. 2002 Mar 8;177(1):29-39. doi: 10.1016/s0304-3835(01)00758-3.
7
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.戈利木单抗，一种新型、双价 CD20 靶向 T 细胞衔接双特异性抗体，在复发或难治性 B 细胞淋巴瘤中诱导持久完全缓解：一项 I 期试验。
J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19.
8
Glofitamab CD20-TCB bispecific antibody.戈利木单抗CD20-TCB双特异性抗体。
Leuk Lymphoma. 2021 Dec;62(13):3098-3108. doi: 10.1080/10428194.2021.1953016. Epub 2021 Jul 15.
9
Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.纳入CD28和TLR2细胞内结构域的第三代CD19嵌合抗原受体T细胞治疗合并中枢神经系统受累的B细胞恶性肿瘤的疗效和安全性：一项关键试验的结果
J Transl Med. 2025 May 27;23(1):594. doi: 10.1186/s12967-025-06608-x.
10
A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.双特异性抗体通过同时靶向CD20和HLA-DR直接诱导淋巴瘤细胞死亡。
J Cancer Res Clin Oncol. 2015 Nov;141(11):1899-907. doi: 10.1007/s00432-015-1949-7. Epub 2015 Mar 14.

引用本文的文献

1
The Landscape of Primary Central Nervous System Lymphoma (PCNSL): Clinicopathologic and Genomic Characteristics and Therapeutic Perspectives.原发性中枢神经系统淋巴瘤（PCNSL）概述：临床病理及基因组特征与治疗前景
Cancers (Basel). 2025 Sep 4;17(17):2909. doi: 10.3390/cancers17172909.
2
Glofitamab treatment of Richter transformation with isolated central nervous system involvement: a case report.戈利妥单抗治疗孤立性中枢神经系统受累的Richter转化：一例报告
Front Immunol. 2025 Jul 18;16:1635589. doi: 10.3389/fimmu.2025.1635589. eCollection 2025.
3
From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies.从分子精准到临床实践：血液系统恶性肿瘤中双特异性和三特异性抗体的综合综述
Int J Mol Sci. 2025 Jun 1;26(11):5319. doi: 10.3390/ijms26115319.
4
Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis.奥雷巴替尼联合利妥昔单抗及大剂量甲氨蝶呤治疗原发性或继发性中枢神经系统弥漫性大B细胞淋巴瘤的疗效及安全性：一项回顾性分析
Invest New Drugs. 2025 May 31. doi: 10.1007/s10637-025-01542-7.
5
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition.嵌合抗原受体T细胞疗法治疗原发性或继发性中枢神经系统淋巴瘤患者的疗效和安全性：一项代表欧洲血液与骨髓移植协会（EBMT）和GoCART联盟开展的研究
Hemasphere. 2025 May 21;9(5):e70146. doi: 10.1002/hem3.70146. eCollection 2025 May.
6
In the era of targeted therapy and immunotherapy: advances in the treatment of large B-cell lymphoma of immune-privileged sites.在靶向治疗和免疫治疗时代：免疫豁免部位大B细胞淋巴瘤的治疗进展
Front Immunol. 2025 Apr 1;16:1547377. doi: 10.3389/fimmu.2025.1547377. eCollection 2025.
7
Advances in primary large B-cell lymphoma of immune-privileged sites.免疫豁免部位原发性大B细胞淋巴瘤的研究进展
Front Immunol. 2025 Feb 26;16:1533444. doi: 10.3389/fimmu.2025.1533444. eCollection 2025.
8
The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.双特异性抗体在B细胞非霍奇金淋巴瘤中的研发与应用
J Pers Med. 2025 Jan 28;15(2):51. doi: 10.3390/jpm15020051.

本文引用的文献

1
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.依帕珠单抗，一种新型皮下注射 CD3xCD20 双特异性 T 细胞接合抗体，用于治疗复发/难治性大 B 细胞淋巴瘤：一项 I/II 期试验的剂量扩展。
J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22.
2
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.戈利木单抗治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913. Epub 2022 Dec 11.
3
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities.双特异性抗体治疗 B 细胞淋巴瘤：前景、未知与机遇
Blood. 2023 Feb 2;141(5):467-480. doi: 10.1182/blood.2021011994.
4
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.在复发或难治性滤泡淋巴瘤患者中，双特异性抗体 mosunetuzumab 的安全性和疗效：一项单臂、多中心、2 期研究。
Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5.
5
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.单药莫昔单抗在复发或难治性 B 细胞淋巴瘤患者中显示出持久的完全缓解：I 期剂量递增研究。
J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16.
6
Primary central nervous system lymphoma.原发性中枢神经系统淋巴瘤。
Blood. 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377.
7
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.戈利木单抗，一种新型、双价 CD20 靶向 T 细胞衔接双特异性抗体，在复发或难治性 B 细胞淋巴瘤中诱导持久完全缓解：一项 I 期试验。
J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19.
8
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.MATRix-RICE 治疗联合自体造血干细胞移植治疗原发性中枢神经系统弥漫性大 B 细胞淋巴瘤（MARIETTA）：一项国际、单臂、2 期临床试验。
Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5.
9
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.DuoBody-CD3xCD20 在临床前模型中可诱导强烈的 T 细胞介导的恶性 B 细胞杀伤作用，并为皮下给药提供了机会。
EBioMedicine. 2020 Feb;52:102625. doi: 10.1016/j.ebiom.2019.102625. Epub 2020 Jan 23.
10
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.CD20-TCB 联合奥滨尤妥珠单抗预处理用于血液系统恶性肿瘤的下一代治疗。
Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1.

格罗菲他单抗可刺激中枢神经系统肿瘤的免疫细胞浸润，并在继发性中枢神经系统淋巴瘤中诱导临床应答。

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.

机构信息

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.

Department of Pathology, City of Hope, Duarte, CA.

出版信息

Blood. 2024 Jul 25;144(4):457-461. doi: 10.1182/blood.2024024168.

DOI:10.1182/blood.2024024168
PMID:38484137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11302446/
Abstract

Although CD20×CD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in central nervous system (CNS) lymphoma is unknown. Here, we report the CD20×CD3 bispecific glofitamab penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces clinical responses in patients with secondary CNS.

摘要

虽然 CD20×CD3 双特异性抗体对系统性 B 细胞淋巴瘤有效，但它们在中枢神经系统（CNS）淋巴瘤中的疗效尚不清楚。在这里，我们报告 CD20×CD3 双特异性 glofitamab 可穿透血脑屏障，刺激免疫细胞浸润 CNS 肿瘤，并在继发性 CNS 患者中诱导临床反应。